Use of Human Perivascular Stem Cells for Bone Regeneration

Dental and Craniofacial Research Institute and Section of Orthodontics, School of Dentistry, UCLA, USA.
Journal of Visualized Experiments (Impact Factor: 1.33). 05/2012; DOI: 10.3791/2952
Source: PubMed


Human perivascular stem cells (PSCs) can be isolated in sufficient numbers from multiple tissues for purposes of skeletal tissue engineering. PSCs are a FACS-sorted population of 'pericytes' (CD146+CD34-CD45-) and 'adventitial cells' (CD146-CD34+CD45-), each of which we have previously reported to have properties of mesenchymal stem cells. PSCs, like MSCs, are able to undergo osteogenic differentiation, as well as secrete pro-osteogenic cytokines. In the present protocol, we demonstrate the osteogenicity of PSCs in several animal models including a muscle pouch implantation in SCID (severe combined immunodeficient) mice, a SCID mouse calvarial defect and a femoral segmental defect (FSD) in athymic rats. The thigh muscle pouch model is used to assess ectopic bone formation. Calvarial defects are centered on the parietal bone and are standardly 4 mm in diameter (critically sized). FSDs are bicortical and are stabilized with a polyethylene bar and K-wires. The FSD described is also a critical size defect, which does not significantly heal on its own. In contrast, if stem cells or growth factors are added to the defect site, significant bone regeneration can be appreciated. The overall goal of PSC xenografting is to demonstrate the osteogenic capability of this cell type in both ectopic and orthotopic bone regeneration models.

Download full-text


Available from: Aaron W James, Jan 05, 2014
22 Reads
    • "Here we found CD146-expressing stromal cells but this finding does not indicate whether they are stem or progenitor cells, neither their exact origin. Actually, accumulating evidence supports the fact that the adult MSCs and HSCs niches are universally vascular/perivascular (Crisan et al., 2008; Chen et al., 2009; Corselli et al., 2010; Chen et al., 2012; Crisan et al., 2012; Ding et al., 2012; James et al., 2012; Zimmerlin et al., 2012; Corselli et al., 2013; Rusu et al., 2014a; Vrapciu et al., 2014a; Rusu and Vrapciu, 2015). This is supported here by the expression of nestin in the SM pericytes which is not an uncommon finding, as it was previously reported in other tissues such as brain (Alliot et al., 1999; Takamori et al., 2009), retina (Lee et al., 2012) or pancreas (Lardon et al., 2002). "
    [Show abstract] [Hide abstract]
    ABSTRACT: An innate osteogenic potential of the Schneiderian membrane (SM) is progressively assessed in studies ranging from non-human species to human subjects. It has relevance for endosteal placement and osseointegration. Nestin-expressing osteogenic progenitor cells are allegedly involved in bone formation and remodelling. Nestin phenotype was not assessed previously in human SM. We therefore aimed to fill that particular gap in the literature. Bioptic samples of human adult SM were obtained during surgery from eight adult patients, operated for non-malignant pathologies. Immunohistochemistry on paraffin-embedded tissue samples used primary antibodies against nestin, CD45, CD146, cytokeratin 7 (CK7) and alpha-smooth muscle actin (α-SMA). Nestin expression was consistently found in endothelial cells, and was scarcely encountered in pericytes, putative stromal stem/progenitor cells, as well as in glandular epithelial cells. Moreover, woven bone formation in the periosteal layer of the SM can also be regarded as evidence of the osteogenic potential of this membrane. Nestin and CD45 expression in cells of the primary bone supports the osteogenic potential of SM nestin-expressing cells and a possible involvement of hematopoietic stem cells in maxillary sinus floor remodelling. CD146, a known inducer of epithelial-mesenchymal transition (EMT), was expressed in epithelia, as was CK7. Isolated stromal cells were found expressing CD146, CK7 and α-SMA, suggesting that regenerative processes happening in the SM may also involve processes of EMT which generate stem/progenitor cells. This study provides additional evidence for the regenerative potential of the Schneiderian membrane and identifies potential roles for cells of its stem niche in osteogenesis. This article is protected by copyright. All rights reserved.
    The Anatomical Record Advances in Integrative Anatomy and Evolutionary Biology 09/2015; DOI:10.1002/ar.23276 · 1.54 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: An ideal mesenchymal stem cell (MSC) source for bone tissue engineering has yet to be identified. Such an MSC population would be easily harvested in abundance, with minimal morbidity and with high purity. Our laboratories have identified perivascular stem cells (PSCs) as a candidate cell source. PSCs are readily isolatable through fluorescent activated cell sorting from adipose tissue and have been previously shown to be indistinguishable from MSCs in phenotype and differentiation potential. PSCs consist of two distinct cell populations: [1] pericytes (CD146+, CD34-, CD45-), which surround capillaries and microvessels, and [2] adventitial cells (CD146-, CD34+, CD45-), found within the tunica adventitia of large arteries and veins. We previously demonstrated the osteogenic potential of pericytes by examining pericytes derived from human fetal pancreas, and illustrated their in vivo trophic and angiogenic effects. In the present study, we used an intramuscular ectopic bone model to develop the translational potential of our original findings using PSCs (as a combination of pericytes and adventitial cells) from human white adipose tissue. We evaluated human PSC (hPSC)-mediated bone formation and vascularization in vivo. We also examined the effects of hPSCs when combined with the novel craniosynostosis-associated protein, NELL-1 (Nel-like Molecule I). Implants consisting of demineralized bone matrix putty combined with either NELL-1 (3µg/µL), hPSC (2.5 x 105 cells), or hPSC+NELL-1 were inserted in the bicep femoris of SCID mice. Bone growth was evaluated using micro computed tomography, histology and immunohistochemistry over 4 weeks. Results demonstrated the osteogenic potential of hPSCs and the additive effect of hPSC+NELL-1 on bone formation and vasculogenesis. Comparable osteogenesis was observed with NELL-1 as compared to the more commonly used Bone Morphogenetic Protein (BMP)-2. Next, hPSCs induced greater implant vascularization than unsorted stromal vascular fraction (SVF) from patient-matched samples. Finally, we observed an additive effect on implant vascularization with hPSC+NELL-1 by histomorphometry and immunohistochemistry, accompanied by in vitro elaboration of vasculogenic growth factors. These findings hold significant implications for the cell/protein combination therapy hPSC+NELL-1 in the development of strategies for vascularized bone regeneration.
    Tissue Engineering Part A 02/2013; 19(11). DOI:10.1089/ten.TEA.2012.0367 · 4.64 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Mesenchymal stem/stromal cells (MSCs) can regenerate tissues by direct differentiation or indirectly by stimulating angiogenesis, limiting inflammation, and recruiting tissue-specific progenitor cells. MSCs emerge and multiply in long-term cultures of total cells from the bone marrow or multiple other organs. Such a derivation in vitro is simple and convenient, hence popular, but has long precluded understanding of the native identity, tissue distribution, frequency, and natural role of MSCs, which have been defined and validated exclusively in terms of surface marker expression and developmental potential in culture into bone, cartilage, and fat. Such simple, widely accepted criteria uniformly typify MSCs, even though some differences in potential exist, depending on tissue sources. Combined immunohistochemistry, flow cytometry, and cell culture have allowed tracking the artifactual cultured mesenchymal stem/stromal cells back to perivascular anatomical regions. Presently, both pericytes enveloping microvessels and adventitial cells surrounding larger arteries and veins have been described as possible MSC forerunners. While such a vascular association would explain why MSCs have been isolated from virtually all tissues tested, the origin of the MSCs grown from umbilical cord blood remains unknown. In fact, most aspects of the biology of perivascular MSCs are still obscure, from the emergence of these cells in the embryo to the molecular control of their activity in adult tissues. Such dark areas have not compromised intents to use these cells in clinical settings though, in which purified perivascular cells already exhibit decisive advantages over conventional MSCs, including purity, thorough characterization and, principally, total independence from in vitro culture. A growing body of experimental data is currently paving the way to the medical usage of autologous sorted perivascular cells for indications in which MSCs have been previously contemplated or actually used, such as bone regeneration and cardiovascular tissue repair.
    Cellular and Molecular Life Sciences CMLS 10/2013; 71(8). DOI:10.1007/s00018-013-1462-6 · 5.81 Impact Factor
Show more